GSK plc Reports Share Transaction
Ticker: GLAXF · Form: 6-K · Filed: Aug 29, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, sec-filing, company-update
TL;DR
GSK bought back its own shares in August 2025.
AI Summary
GSK plc announced a transaction in its own shares on August 29, 2025. The filing, a Form 6-K, details this activity as part of its reporting for the month of August 2025. GSK plc is a pharmaceutical preparations company based in London, UK.
Why It Matters
This filing indicates GSK plc is actively managing its share capital, which can impact shareholder value and stock performance.
Risk Assessment
Risk Level: low — The filing reports routine share transactions, which typically carry low immediate risk.
Key Players & Entities
- GSK plc (company) — Registrant
- August 2025 (date) — Reporting period
- 20250829 (date) — Filing date
- 001-15170 (other) — SEC File Number
FAQ
What type of transaction did GSK plc report?
GSK plc reported a 'Transaction in own shares'.
What is the filing type and reporting period?
The filing is a Form 6-K, reporting for the month of August 2025.
When was this filing submitted to the SEC?
The filing was submitted on August 29, 2025.
What is GSK plc's primary industry classification?
GSK plc is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What is GSK plc's principal executive office address?
The principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 2,530 words · 10 min read · ~8 pages · Grade level 2.6 · Accepted 2025-08-29 06:44:32
Filing Documents
- a1315x.htm (6-K) — 4793KB
- 0001654954-25-010165.txt ( ) — 4794KB
From the Filing
IN OWN SHARES a1315x   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .                                     Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase: 28 August 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 236,167 Lowest price paid per share (GBp): 1,460.50p Highest price paid per share (GBp): 1,479.00p Volume-weighted average price paid per share (GBp): 1,466.11p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 26,021,500 ordinary shares.   Following the above purchase, the Company will hold 244,155,883 ordinary shares in treasury and have 4,071,236,744 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,071,236,744. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   6.00 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:       GSK plc (ISIN: GB00BN7SWP63)     Date of purchases:       28 August 2025   Investment firm:          Merrill Lynch International     Aggregated information per trading venue:   Venue Number of ordinary shares purchased Highest price paid (per ordinary share) (GBp) Lowest price paid (per ordinary share) (GBp) Volume weighted average price paid (per ordinary share) (GBp) London Stock Exchange (XLON) 236,167 1,479.00p 1,460.50p 1,466.11p CBOE (CHIX) 0 - - - CBOE (BATE) 0 - - -     Individual transactions:   Number of Shares Price per Share (GBp) Trading venue Date of transaction Time of transaction Transaction reference number 8,497 1,478.50  XLON 28-Aug-2025 08:00:24 0XL0614000000000ARCJA0 21 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0610000000000ARCJ6E 21 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0640000000000ARCJD1 21 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0640000000000ARCJD3 22 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0610000000000ARCJ6D 22 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0611000000000ARCJDE 22 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0617000000000ARCJGP 22 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0617000000000ARCJGR 22 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0640000000000ARCJD0 22 1,478.00  XLON 28-Aug-2025 08:00:57 0XL06A0000000000ARCJFB 23 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0611000000000ARCJDF 23 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0611000000000ARCJDH 23 1,478.00  XLON 28-Aug-2025 08:00:57 0XL0617000000000ARCJGO 23 1,478.00  XLON 28-Aug-2025 08:00:57 0XL06170000000